Navigation Links
New Post Hoc Analyses Examined the Effects of Neupro® (Rotigotine Transdermal System) on Daytime Functioning, Daytime Symptoms, Pain and Mood in Restless Legs Syndrome
Date:6/10/2011

symptoms in the evening (or early afternoon), increase in severity of symptoms, and spread of symptoms to involve other body parts.

Adverse drug reactions reported in more than 10% of Parkinson's patients treated with Neupro® are nausea, vomiting, application site reactions, somnolence, dizziness and headache.

Adverse drug reactions reported in more than 10% of RLS patients treated with Neupro® are nausea, application site reactions, asthenic conditions and headache.

All Neupro® supply should be stored in a refrigerator. There is no need for patients to transport Neupro® patches in special containers and they must not be stored in a freezer compartment.

Please refer to the European Summary of Product Characteristics for full prescribing information Neupro® European Summary of Product Characteristics (Approved February 2011) http://ec.europa.eu/health/documents/community-register/html/alfregister.htm

About Neupro® in the U.S.

Neupro® (Rotigotine Transdermal System) is indicated in the U.S. for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease.  Neupro® is not FDA approved for the treatment of Restless Legs Syndrome.

In April 2008, UCB recalled Neupro® from the U.S. market after ongoing monitoring revealed that specific batches of Neupro® had deviated from their approved specification. Neupro® is currently not available in the U.S. UCB is working with the U.S. FDA so that Neupro® can be available to patients with early-stage Parkinson's disease as soon as possible.

Neupro® in the U.S. -  Important Safety Information

Some patients treated with Neupro® reported falling asleep while engaged in activities of daily living, including operation of motor vehicles, which sometimes
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CardioVascular Institute enrolled the first patient in Pennsylvania ... in a trial assessing the safety and effectiveness ... main artery of the leg. The new stent allows for ... stent fracture or re-narrowing after the stent is placed. ... the BioMimics 3D Stent System and will enroll 280 subjects ...
(Date:8/27/2015)...  Lightwave Logic, Inc. (OTCQB: LWLG), a technology ... Generation Photonic Devices and Non-Linear Optical Polymer Materials ... data communications and optical computing, announced today that ... to the Company,s Board of Directors. ... is widely recognized with wide-ranging experience across many ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... Probody™ therapeutics for the treatment of cancer, today ... a member of the company,s Board of Directors, ... formerly led immuno-oncology at Eli Lilly and AstraZeneca, ... the first FDA approved checkpoint inhibitor, at Bristol-Myers ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... May 7, 2012  AssureRx Health, Inc. today announced ... the growing number of children and adults diagnosed ... pharmacogenomic test can assist clinicians with important medication ... individual patients tolerate ADHD medications. ...
...  BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, ... announced the completion of a randomized, controlled trial ... product.  ActiPatch uses pulsed electromagnetic field therapy to ... injured tissue. A double blind, ...
Cached Medicine Technology:AssureRx Health Launches Personalized Medicine Test for ADHD 2AssureRx Health Launches Personalized Medicine Test for ADHD 3BioElectronics' ActiPatch Reduces Muscle Soreness in Runners 2
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... ... 27, 2015 , ... Banc Intranets recently entered into a strategic ... both Johnson City, Tenn.-based firms to work synergistically to promote similar products to the ... caters to organizations in the financial, commercial and services sectors. The software, which is ...
(Date:8/27/2015)... ... 2015 , ... Susan Harris and the team at LifeStream Health ... pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is ... the vaginal tissue, revitalizing cells so they make more collagen, an essential component in ...
(Date:8/27/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and Innovation, ... Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , Ms. ...
(Date:8/27/2015)... ... 2015 , ... Standifer Insurance Group, a full service insurance ... joint charity drive with the Meadow View Elementary School in Alabaster. , A ... many lack the simple supplies necessary for a productive scholastic career. In partnering ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3
... people seeking active participation in their communities has led researchers to ... engagement can now be considered a distinct retirement role, according to ... (Volume 48, Number 3). , The authors ... at least one day per week that directly impact the ...
... hours for participants in phase II trial , , ... drug called pegloticase lowered levels of uric acid in ... in most patients. , That,s the conclusion of a ... Savient Pharmaceuticals, the company that,s developing the drug. ...
... Trim Holdings,Inc. (Amex: ZTM ) announced today ... private placement subscription agreements pursuant to which we,sold ... for an,aggregate offering price of $2,370,000. Each of ... consists of a $100,000 24-month,senior secured promissory note ...
... overwhelmingly positive, PORTLAND, Ore., Sept. 3 ... doctor to others, according to a,popular online survey ... A,"Member Feedback" feature on the site allows Regence ... providers, including,physicians, dentists, other health care professionals and ...
... Amsterdam, September 3, 2008 A recent study (doi:10.1016/j.clim.2008.06.009) ... of the Clinical Immunology Society (CIS), describes a new ... human cells. The report demonstrates the characterization of specific ... providing information about the role these cells might play ...
... new survey by Medical Economics details surprising statistics on earnings and ... in wages for many doctors accompanied by a decrease in patient ... ... 2008 -- A newly-released 2008 Medical Economics survey focusing on earnings ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: